Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics
-
Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer
-
Brilinta approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease
-
Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial
-
Imfinzi showed a sustained overall survival benefit in 1st-line extensive-stage small cell lung cancer in the Phase III CASPIAN trial
-
Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial
-
Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial
-
Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer
-
Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer
-
AstraZeneca collaborates with ArcherDX to use personalised cancer assays to detect minimal residual disease in lung cancer trials
Latest articles and press releases
All of our latest press releases and articles are available to explore
